Ken Griffin Phathom Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $38,571 - $51,815	-4,300 Reduced 47.78%	4,700 $48,000
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $13,662 - $24,310	2,200 Added 32.35%	9,000 $95,000
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $27,960 - $42,840	4,000 Added 142.86%	6,800 $62,000
Q3 2023 Nov 14, 2023	SELL	$10.26 - $15.7 $25,650 - $39,250	-2,500 Reduced 47.17%	2,800 $29,000
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $24,752 - $48,688	3,400 Added 178.95%	5,300 $75,000
Q1 2023 May 15, 2023	SELL	$6.19 - $12.36 $53,234 - $106,296	-8,600 Reduced 81.9%	1,900 $13,000
Q4 2022 Feb 14, 2023	BUY	$9.18 - $11.53 $96,390 - $121,065	10,500 New	10,500 $117,000

126

59.6M

467K

34.9K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $705M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.